FDA-cleared profile

AI4CMR v1.0

AI4MedImaging Medical Solutions S.A. · MRI · FDA-cleared (510(k))

Authorized purpose: Automatic segmentation and reporting of cardiac function measurements from 1.5T and 3T MR images to support clinical decision-making; results are not intended for standalone clinical decision-making.

Clinical role
Post-processing cardiac MR segmentation and quantification through a plug-in to a third-party DICOM viewer, with results made available to the user for review and reporting.
Images and patients
MRI · Heart, including left and right ventricles, myocardium, and cardiac chambers
Key limitation
Keep in mind: Results are not for standalone clinical decision-making, and the user is responsible for implementing the DICOM viewer user interface. Indices derived from height and weight are available only when those values are included in the DICOM data. The FDA evidence uses small bench and retrospective MRMC datasets across specified 1.5T/3T scanners and establishes measurement agreement and segmentation endpoints rather than autonomous diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatic segmentation and reporting of cardiac function measurements from 1.5T and 3T MR images to support clinical decision-making; results are not intended for standalone clinical decision-making.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Heart, including left and right ventricles, myocardium, and cardiac chambers Input: Cardiac MR images from 1.5T and 3T scanners, including multi-slice MR data received through a DICOM viewer that provides the user interface and connection to a PACS or scanner.
  • Who uses it?Intended users: The user incorporating AI4CMR into a DICOM application of choice
  • What does the software produce?Output: Anatomical and tissue segmentation; LV/RV stroke volume, cardiac output, ejection fraction, end-diastolic volume, end-systolic volume, and myocardial mass; derived indices when required patient height and weight are present in DICOM; and report or DICOM Secondary Capture outputs.
  • What is its most important limitation?Key limitation: Results are not for standalone clinical decision-making, and the user is responsible for implementing the DICOM viewer user interface. Indices derived from height and weight are available only when those values are included in the DICOM data. The FDA evidence uses small bench and retrospective MRMC datasets across specified 1.5T/3T scanners and establishes measurement agreement and segmentation endpoints rather than autonomous diagnosis.

Clinical takeaway. Clinical role: Automatic segmentation and reporting of cardiac function measurements from 1.5T and 3T MR images to support clinical decision-making; results are not intended for standalone clinical decision-making.

Evidence takeaway. Evidence from the reviewed source record: FDA bench testing used 15 CMR cases annotated by seven independent expert readers across 1.5T and 3T Siemens, GE, and Philips scanners; average myocardium segmentation Dice similarity coefficient was 0.72. Reported measurement agreement included LV EF bias 3.87 (SD 5.74), LV ICC 0.96; RV EF bias 7.80 (7.32), RV ICC 0.81; LV EDV bias 8.66 (17.28), LV ICC 0.99; RV EDV bias 8.36 (15.59), RV ICC 0.96; LV ESV bias -2.90 (17.52), LV ICC 0.99; RV ESV bias -9.08 (13.83), RV ICC 0.95; and LV myocardial-mass bias 2.45 (18.04), ICC 0.96. The retrospective MRMC clinical performance assessment used 146 CMR cases and two expert readers to evaluate agreement with manual segmentation and measurements; the reviewed text does not provide a single diagnostic sensitivity or specificity result.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatic segmentation and reporting of cardiac function measurements from 1.5T and 3T MR images to support clinical decision-making; results are not intended for standalone clinical decision-making.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Post-processing cardiac MR segmentation and quantification through a plug-in to a third-party DICOM viewer, with results made available to the user for review and reporting.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Cardiac MR images from 1.5T and 3T scanners, including multi-slice MR data received through a DICOM viewer that provides the user interface and connection to a PACS or scanner.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Anatomical and tissue segmentation; LV/RV stroke volume, cardiac output, ejection fraction, end-diastolic volume, end-systolic volume, and myocardial mass; derived indices when required patient height and weight are present in DICOM; and report or DICOM Secondary Capture outputs.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Healthcare setting using a third-party DICOM viewer connected to a PACS or scanner; the FDA packet does not specify a more specific facility type.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
The user incorporating AI4CMR into a DICOM application of choice
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Results are not for standalone clinical decision-making, and the user is responsible for implementing the DICOM viewer user interface. Indices derived from height and weight are available only when those values are included in the DICOM data. The FDA evidence uses small bench and retrospective MRMC datasets across specified 1.5T/3T scanners and establishes measurement agreement and segmentation endpoints rather than autonomous diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA bench testing used 15 CMR cases annotated by seven independent expert readers across 1.5T and 3T Siemens, GE, and Philips scanners; average myocardium segmentation Dice similarity coefficient was 0.72. Reported measurement agreement included LV EF bias 3.87 (SD 5.74), LV ICC 0.96; RV EF bias 7.80 (7.32), RV ICC 0.81; LV EDV bias 8.66 (17.28), LV ICC 0.99; RV EDV bias 8.36 (15.59), RV ICC 0.96; LV ESV bias -2.90 (17.52), LV ICC 0.99; RV ESV bias -9.08 (13.83), RV ICC 0.95; and LV myocardial-mass bias 2.45 (18.04), ICC 0.96. The retrospective MRMC clinical performance assessment used 146 CMR cases and two expert readers to evaluate agreement with manual segmentation and measurements; the reviewed text does not provide a single diagnostic sensitivity or specificity result.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA bench testing used 15 CMR cases annotated by seven independent expert readers across 1.5T and 3T Siemens, GE, and Philips scanners; average myocardium segmentation Dice similarity coefficient was 0.72. Reported measurement agreement included LV EF bias 3.87 (SD 5.74), LV ICC 0.96; RV EF bias 7.80 (7.32), RV ICC 0.81; LV EDV bias 8.66 (17.28), LV ICC 0.99; RV EDV bias 8.36 (15.59), RV ICC 0.96; LV ESV bias -2.90 (17.52), LV ICC 0.99; RV ESV bias -9.08 (13.83), RV ICC 0.95; and LV myocardial-mass bias 2.45 (18.04), ICC 0.96. The retrospective MRMC clinical performance assessment used 146 CMR cases and two expert readers to evaluate agreement with manual segmentation and measurements; the reviewed text does not provide a single diagnostic sensitivity or specificity result.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

AI4CMR v1.0 regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K220624
  • Samplen=15
  • IndependenceIndependence not established

K220624

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K220624. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Cardiac MR images from 1.5T and 3T scanners, including multi-slice MR data received through a DICOM viewer that provides the user interface and connection to a PACS or scanner.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K220624: AI4CMR v1.0

  2. Routing

    Source context, not route validation: AI4CMR is described as a cloud-hosted service implemented as a plug-in to any third-party DICOM viewer; the viewer serves as the user interface and the interface to a PACS or scanner. DICOM input and report/DICOM Secondary Capture output are described, but specific PACS, RIS, EHR, interface versions, and current local compatibility are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K220624: AI4CMR v1.0

  3. AI processing

    Source context, not route validation: The exact FDA package describes AI4CMR v1.0 as a cloud-hosted service implemented by the user as a plug-in to a third-party DICOM viewer, which serves as its user interface and its interface to a PACS or scanner. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "AI4CMR v1.0 is a cloud-hosted service used with any third-party DICOM viewer application where the DICOM viewer serves as the user interface and the interface to a PACS or scanner for AI4CMR." … "AI4CMR is implemented as a plug-in to the DICOM viewer by the user". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K220624: AI4CMR v1.0

  4. Returned objects

    Source context, not route validation: Anatomical and tissue segmentation; LV/RV stroke volume, cardiac output, ejection fraction, end-diastolic volume, end-systolic volume, and myocardial mass; derived indices when required patient height and weight are present in DICOM; and report or DICOM Secondary Capture outputs.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K220624: AI4CMR v1.0

  5. Viewer/worklist/report

    Unresolved route: Anatomical and tissue segmentation; LV/RV stroke volume, cardiac output, ejection fraction, end-diastolic volume, end-systolic volume, and myocardial mass; derived indices when required patient height and weight are present in DICOM; and report or DICOM Secondary Capture outputs.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K220624: AI4CMR v1.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes AI4CMR v1.0 as a cloud-hosted service implemented by the user as a plug-in to a third-party DICOM viewer, which serves as its user interface and its interface to a PACS or scanner. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "AI4CMR v1.0 is a cloud-hosted service used with any third-party DICOM viewer application where the DICOM viewer serves as the user interface and the interface to a PACS or scanner for AI4CMR." … "AI4CMR is implemented as a plug-in to the DICOM viewer by the user". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
AI4CMR is described as a cloud-hosted service implemented as a plug-in to any third-party DICOM viewer; the viewer serves as the user interface and the interface to a PACS or scanner. DICOM input and report/DICOM Secondary Capture output are described, but specific PACS, RIS, EHR, interface versions, and current local compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-08
Security
AI4CMR's security & compliance page states that AI4CMR operates cloud sites in multiple global regions so that data remains within the appropriate jurisdiction in compliance with GDPR and local data-protection regulations, and maintains cloud-based disaster recovery systems to preserve availability and data integrity.
  • Product family
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names the AI4CMR product without distinguishing v1.0 (K220624) from v2.0 (K252084); exact-release scope is not established. The page's listed QMS/regulatory standards (ISO 13485, ISO 14971, IEC 62304, MDR, 21 CFR 820) are not treated as security evidence; no certificate or report was read.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for AI4CMR v1.0; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220624
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Heart, including left and right ventricles, myocardium, and cardiac chambers
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-07-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K220624 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K220624: AI4CMR v1.0

    U.S. Food and Drug Administration - Published 2022-07-22 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AI4CMR v1.0 model card (K220624)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K220624

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. AI4CMR: Security & Compliance

    AI4MedImaging Medical Solutions S.A. - Accessed 2026-10-27

    Scope: security

Research history

  1. K220624 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252084

AI4CMR v2.0

Ai4medimaging Medical Solutions S.A.

Authorized purpose: Cardiac MRI ventricular function and 2D phase-contrast flow quantification

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2026-02-11
FDA-cleared K241922

Myomics

Phantomics Inc.

Authorized purpose: Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2025-02-28
FDA-cleared K241312

TeraRecon Cardiac.Chambers.MR (1.0.0)

TeraRecon,Inc.

Authorized purpose: Provide cardiac-chamber segmentations for trained healthcare professionals reviewing adult cardiac MR to assist diagnosis or treatment planning; the physician makes final patient-management decisions.

Modality
MRI
Anatomy
Cardiac chambers: left-ventricular myocardium and chamber, and right-ventricular chamber for the Cine-ax component; left-ventricular myocardium and chamber for the De-ax component.
Decision
2024-11-05
FDA-cleared K232661

Myocardial Strain Software Application

Circle Cardiovascular Imaging

Authorized purpose: Myocardial Strain Software Application provides qualitative and quantitative evaluation of cardiovascular MR images, including two-dimensional displacement, velocity, strain, strain rate, time to peak, and torsion after a qualified user confirms the contours.

Modality
MRI
Anatomy
Heart; left ventricular myocardium and cardiovascular structures
Decision
2023-12-07

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history